ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Feinstein Institutes’ Scientists Find Common Blood Pressure Drug Could Be Beneficial in Some Cases of Autism

Findings published in Molecular Psychiatry reveal that captopril restores the health of brain immune cells, reversing autism-like traits linked to maternal autoantibodies

Scientists at Northwell Health’s Feinstein Institutes for Medical Research have made a significant discovery in Autism Spectrum Disorder (ASD): a widely used blood pressure medication, captopril, can restore healthy function to the brain’s immune cells and reverse ASD-like behaviors in a preclinical animal model. This invaluable research focuses on a specific type of ASD believed to be triggered by a mother’s immune system during pregnancy and could better understand autism and autism-like symptoms.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251024872426/en/

Dr. Lior Brimberg led the study. (Credit: Feinstein Institutes).

Dr. Lior Brimberg led the study. (Credit: Feinstein Institutes).

Published this week in Molecular Psychiatry, these findings build on previous research that showed how a mother’s antibodies, if they target a specific brain protein during fetal development, can lead to ASD-related symptoms, especially in male offspring. In those studies, researchers found that the brain’s immune cells, called microglia, became overactive and unhealthy, disrupting crucial brain cell connections and affecting social behavior.

The study, led by Lior Brimberg, PhD, associate professor in the Institute of Molecular Medicine at the Feinstein Institutes, and Ben Spielman, an MD/PhD candidate at the Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, found that when captopril – known for its ability to cross the blood-brain barrier – was given in this preclinical model of ASD, it significantly calmed the active microglia and increased social interaction.

“Understanding Autism Spectrum Disorder is incredibly complex, but for some individuals, research has shown that the condition may stem from immune system activation during early fetal brain development,” said Dr. Brimberg, who is also corresponding author of the paper. “Our new work shows that a commonly used drug for blood pressure, captopril, can help quite down these brain immune cells, offering a promising new path for targeted treatment.”

The study shows that by using this drug, it helped rebuild vital brain connections and nerve cell growth, and importantly, led to increased social interaction. By analyzing the microglia’s inner workings, scientists found captopril boosted their energy and protein production, directly connecting this cellular rebalancing to improvements in brain structure and behavior.

“Dr. Brimberg and colleagues have uncovered important new evidence about the role of neuroinflammation in autism, showing how precisely targeting dysfunctional microglia with an existing drug can affect brain function,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “This rigorous research advances our understanding of neural-immune interactions and opens new possibilities for treating specific forms of neurodevelopmental disorders through targeted molecular intervention.”

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.